CD276 and nonpapillary renal cell carcinoma: Among these candidate targets, avelumab is the only approved agent in metastatic ccRCC (in combination with axitinib)5, while inhibitors of B7-H3 and agonists of 4-1BB/4-1BBL remain largely unexplored in RCC.